reason report
expect anoth strong year us temper
bottom line commerci launch robust
first yr updat guidanc
two increas revis expect management provid
guidanc januari believ new/consensu estim
achiev given mount clinic experi
loosen reimburs dynam among payor link
updat estim incorpor qoq pt growth
like achiev introduct
op insur live reiter op pt
us sale estim reflect pt qoq
growth believ wareh effect like contribut robust
launch trajectori qoq growth
recent introduct coverag estim
anoth pt may elig reimburs treatment exhibit
genet test becom commonplac among dmd pt
believ pt like trickl throughout
beyond render consensu number within reach
wrote previous loosen coverag polici could
reverber smaller region payor cover
sinc reimburs discuss must take place country-
by-countri basi potenti ema approv sale
may ramp slower previous forecast consequ
lower eu sale estim vs
reflect dynam off-set partli potenti name patient sale
ex-u eu present larger dmd popul vs
us investor may recal european pt advoc
attend eteplirsen advisori committe adcom panel
underscor demand howev differ newborn
screen polici across eu could influenc launch eteplirsen
approv estim probabl given special
circumst led approv us previou guidanc
ema dystrophin consid valid surrog endpoint
pend formal updat estimate reflect
increas sale benefit approv
therapi exon skip-amen dmd pt long reimburs
polici remain unperturb recent management commentari
favor pt complianc discontinu rate concurr
increas start form genet test request therefor
see materi headwind
treatment initi younger pt rel average yr old
treatment option pt like becom consist sourc
revenu better competitor agent emerg
compani inform leerink partner llc research
revenu million ep
net debt total capit
pleas refer page import disclosur price chart analyst certif
approv eteplirsen exondi sept address approxim
duchenn muscular dystrophi dmd patient suffer mutat dystrophin gene
amen exon estim eteplirsen applic
dmd patient eu use proprietari phosphorodiamid
morpholino oligom pmo chemistri develop exon skip drug
oper mechan may abl amelior
progress dmd patient variou disease-caus mutat consid
rariti sever dmd lack optim treatment prevent progress muscl
deterior lead complic respiratori cardiac function afflict boy
expedited/mor lenient path approv may possibl eteplirsen/exondi
addit vocal patient-advocaci group new administr seem favor
acceler treatment option rare diseas link could provid tailwind program
develop sarepta current model peak probability-weight eteplirsen/
exondi ww revenu addit revenu deriv
follow-on candid meanwhil sarepta on-going
work suggest peptide-conjug pmo ppmo could gener even greater efficaci
dystrophin restor superior pmo-bas candid pend satisfactori progress
near term first ppmo candid could gener clinic data lastli sarepta
diversifi approach forg collabor partnership nationwid children
hospit summit smmt nr catabasi catb nr investig mechan
could benefit dmd patient either monotherapi synergist sarepta
drug candid success intern extern program could provid
upsid stock
estim risk-adjust per share fair valu month current
model peak probability-weight eteplirsen/exondi ww revenu
addit revenu deriv follow-on candid
eteplirsen/exondi rest
net cash use wacc discount rate sinc announc eteplirsen
exondi fda approv assum us eu probabl eteplirsen/
exondi approv commerci success longer term assum termin
growth rate may warrant adjust pend fda decis confirmatori studi
sinc eteplirsen stand valid mechan action subsequ exon-skipp
assign probabl success po us/
eu respect po potenti launch respect
risk includ potenti disappoint clinic data regulatori setback commerci
shortfal sinc present one product later-stag clinic trial pipelin
util chemic formul possibl setback may impact stock
exhibit coverag could present tailwind new patient
commerci live cover live cover male male yr male yr old dmd prevalencelow dmd pt dmd pt elig elig health group total enrol mm inc
exhibit street consensu estim come appear reachabl
sourc factset jan leerink partner research
sale us eu golodirsen golodirsen leerink golodirsen- golodirsen leerink leerink inc
litig licens charg
chang
equiti
clinic regulatori mileston
final protocol confirmatori trial submiss
phase essenc enrol complet
fda regulatori meet golodirsen
phase ii data ezutromid
amen exon skip
patient eteplirsen
treat eteplirsen
amen exon skip
patient eteplirsen
treat eteplirsen
royalti commit ww
compani report leerink partner estim
